Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 5495SC

5495SC 100 µg (With Carrier) $199.00
5495SF 100 µg (Carrier Free) $199.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human TGF-α (hTGF-α) Val40-Ala89 (Accession #NP_003227) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-α. All lots are greater than 98% pure.


Molecular Formula:

Based on amino acid sequencing, greater than 50% of recombinant hTGF-α has a Met on the amino-terminal Val40 (MVVSH) and has a calculated MW of 5,683. The remainder starts at Val40 (VVSHF). DTT-reduced and non-reduced protein migrate as 5 kDa polypeptides.


Bioactivity:

The bioactivity of recombinant hTGF-α was determined in a MCF-10A cell proliferation assay. The ED50 of each lot is between 0.25-1.0 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hTGF-α.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hTGF-α. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

TGF-α is a member of the EGF family of proteins and is expressed by epithelial cells, keratinocytes, macrophages, and many tumor-derived cell lines (1-4). Soluble TGF-α is produced by proteolytic cleavage of a transmembrane precursor (5). TGF-α promotes cell proliferation and differentiation of a diverse array of cell types including cancer and neural cells (1,4,6). TGF-α binds to EGFR/ErbB1 and induces receptor dimerization and tyrosine kinase activation (7). TGF-α activates the MAPK pathways and involves Stat3 and Stat5 (1,6). Increased levels of TGF-α expression are associated with many cancers including breast cancer (1,8,9).


1.  Humphreys, R.C. and Hennighausen, L. (2000) Oncogene 19, 1085-91.

2.  Citri, A. and Yarden, Y. (2006) Nat Rev Mol Cell Biol 7, 505-16.

3.  Rappolee, D.A. et al. (1988) Science 241, 708-12.

4.  Higashiyama, S. et al. (2008) Cancer Sci 99, 214-20.

5.  Xu, X. et al. (1999) Oncogene 18, 5554-62.

6.  Ciana, P. et al. (2003) J Biol Chem 278, 31737-44.

7.  Song, J.I. and Grandis, J.R. (2000) Oncogene 19, 2489-95.

8.  Révillion, F. et al. (2008) Ann Oncol 19, 73-80.

9.  Masago, K. et al. (2008) Cancer Sci 99, 2295-301.


Entrez-Gene Id 7039
Swiss-Prot Acc. P01135


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.